For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
|Videos|January 24, 2023
Emerging Insights on MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Author(s)Jeff Hall
In a recent video interview, Amar Kishan, M.D., discussed a new study that demonstrated significant side effect reduction when utilizing magnetic resonance imaging (MRI) guidance instead of computed tomography (CT) guidance for stereotactic body radiation therapy (SBRT) to treat localized prostate cancer.
Advertisement
Emerging research suggests that magnetic resonance imaging (MRI) guidance may be more advantageous than computed tomography (CT) guidance for reducing the side effects of stereotactic body radiation therapy (SBRT) in the treatment of prostate cancer.
Results from the phase 3 randomized trial, recently published in
In a recent video interview, lead study author Amar Kishan, M.D. called the MRIdian LINAC (ViewRay) a “major technological breakthrough” that allows physicians to combine continuous MRI imaging with a more targeted radiation delivery system for
“(With) these advanced precision and accuracy capabilities, particularly that high degree of tracking during the treatment, we felt we could reduce the margins around the prostate that we need to treat from four millimeters to two millimeters,” explained Dr. Kishan, an associate professor, vice-chair of Clinical and Translational Research and chief of the Genitourinary Oncology Service within the Department of Radiation Oncology at UCLA.
For more insights from Dr. Kishan, watch the video below.
Advertisement
Related to this article
Catch up on the top radiology content of the past week.
For patients with metastatic castration-resistant prostate cancer (mCRPC), researchers found that (177Lu)Lu-PSMA-I&T led to a PSA50 response in over 44 percent of patients with no reports of grade 3 or worse renal toxicity, according to a newly published multicenter study.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
2
Prostate MRI Study Links Lower ACD Values on DWI to Higher Long-Term Risk of Distant Metastases
3
Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
4
Brain MRI Study Reveals Higher Brain Age Gap and White Matter Hyperintensity for Those in Disadvantaged Neighborhoods
5